01—Abstract
Summary
Summary of the 8-K filed March 3, 2025. Cited figures are marked; the original filing is the authoritative source.
On March 3, 2025, Isomedix Operations, Inc., a subsidiary of STERIS plc, entered into binding confidential term sheets with plaintiffs' counsel and settlement agreements with several plaintiffs scheduled for trial.
The agreements are expected to resolve substantially all pending personal injury claims related to ethylene oxide (EO) in the Circuit Court of Cook County, Illinois. Under the term sheets, Isomedix has entered into, and expects to enter into, additional agreements to pay up to $48.15 milliona to settle claims. The filing states that neither the term sheets nor the agreements are an admission of liability or an admission that emissions from the Waukegan, Illinois facility posed a safety hazard.
The settlement will be funded with cash on hand and borrowings under the existing revolving credit facility, with settlement funds deposited into escrow with a mutually agreed escrow agent. A claims administration process, expected to take up to 10 months, will govern individual settlements. STERIS will record a charge for the settlement in the fiscal year ended March 31, 2025, and will exclude it from its fiscal 2025 adjusted earnings measures.
Isomedix anticipates dismissal of all pending EO-related claims by covered plaintiffs once claims administration is complete and the court approves. Isomedix may exercise walkaway rights if agreed terms are not met, including if a substantial majority of plaintiffs do not agree to settle, are disqualified, or if the court does not approve the settlements. If it does so, Isomedix states it will continue to defend the litigation and reserves all legal and factual defenses.
02—Key points
Key Highlights
- Isomedix, a STERIS subsidiary, entered into binding confidential term sheets and settlement agreements resolving substantially all pending personal injury claims related to ethylene oxide in Cook County, Illinois.
- Isomedix agreed to pay up to $48.15 million to settle claims under the term sheets, with additional agreements expected.
- The settlement is funded with a mix of cash on hand and borrowings under the existing revolving credit facility, with funds deposited into escrow.
- STERIS will record a charge for the settlement in the fiscal year ended March 31, 2025, excluded from fiscal 2025 adjusted earnings measures.
- Claims administration is expected to take up to 10 months to complete, after which Isomedix anticipates dismissal of all pending EO-related claims by covered plaintiffs, subject to court approval.
- Isomedix may exercise walkaway rights if a substantial majority of plaintiffs do not settle, are disqualified, or if the court does not approve the settlements.
- The filing states that the settlement is not an admission of liability or that Waukegan, Illinois facility emissions posed a safety hazard.
03—Questions
Frequently Asked Questions
How much is STERIS paying to settle the ethylene oxide claims?
Under the term sheets, Isomedix has entered into and expects to enter into additional agreements to pay up to $48.15 million to settle claims.
How will the settlement be paid for?
The settlement will be funded with a mix of cash on hand and borrowings under the existing revolving credit facility. Settlement funds will be deposited into escrow with a mutually agreed escrow agent.
How will the settlement affect STERIS's reported earnings?
STERIS will record a charge for the settlement in the fiscal year ended March 31, 2025. The company stated that this charge will be excluded from its fiscal 2025 adjusted earnings measures.
When will the settlement process be completed?
The claims administration process, which governs individual settlements, is expected to take up to 10 months to complete. Isomedix anticipates dismissal of all pending EO-related claims by covered plaintiffs upon completion of that process and court approval.
Could the settlement fall apart?
Yes. Isomedix may exercise walkaway rights if agreed terms are not fulfilled, including if a substantial majority of plaintiffs do not agree to settle or are disqualified, or if the court does not approve the resulting settlements. In that case, Isomedix is prepared to continue defending the litigation and reserves all legal and factual defenses.
04—Continue